MedTrace Logo

Novel Treatment of Advanced Hepatocellular Carcinoma

NCT03950518 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with Levamisole in the treatment of patients with hepatocellular carcinoma.

Conditions

Interventions

DRUG

Anlotinib Hydrochloride Capsules

Anlotinib Hydrochloride Capsules, 12mg/d

DRUG

Arginine hydrochloride

AHC,12mg/d AH,40g/d

DRUG

levamisole

AHC,12mg/d AH,40mg/d LM,150mg/d

Sponsors & Collaborators

  • Luoyang Central Hospital

    collaborator OTHER

  • Nanyang Central Hospital

    collaborator OTHER

  • Anyang Tumor Hospital

    collaborator OTHER

  • The Third People's Hospital of Jiaozuo

    collaborator UNKNOWN

  • Sanmenxia Central Hospital

    collaborator UNKNOWN

  • Pingdingshan Coal Medical Group General Hospital

    collaborator UNKNOWN

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2023-04-10
Completion
2023-04-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03950518 on ClinicalTrials.gov